Allogene Therapeutics (ALLO) Competitor Comparison
We are evaluating the key criteria listed to compare Allogene Therapeutics (ALLO) against its competitors in the Biotechnology industry.
Market Capitalization
136 / 368Gross Profits
139 / 278Total Revenue
270 / 300EBITDA
307 / 337Free Cashflow
309 / 352Quick Ratio
61 / 357Earnings per Share
177 / 359Dividend yield
0 / 6Total Cash
69 / 358Performance 3 years
264 / 368Performance 5 years
273 / 368Performance 10 years
228 / 368Linearity 3 years
225 / 368Linearity 5 years
184 / 368Linearity 10 years
141 / 368Total Rank
285 / 368Dividend Rank
342 / 368Valuation Rank
262 / 368Piotroski Rank
254 / 368Muliplier Rank
260 / 368Performance 3 years - ALLO ranking 264 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.